Press release from Companies
Publicerat: 2022-04-29 08:00:00
Oslo, Norway, April 29, 2022 - Genetic Analysis AS (the "Company", Ticker: GEAN) held its Annual General Meeting on April 28 at 15:00 hours (CET) on the Company's premises in Kabelgata 8, Oslo.
The agenda for the meeting was as follows: 1. Election of a chairperson and a person to co-sign the minutes Kathryn M. Baker was elected to chair the general meeting. The Chairperson ascertained the lawfulness of the general meeting. Eilert Aamodt was elected to co-sign the minutes. 2. Approval of the annual accounts and directors’ report of Genetic Analysis AS for 2021, including allocation of the result of the year The general meeting unanimously approved the annual accounts and the Directors' Report for the Company for 2021, including the board of directors' proposal for allocation of the result of the year. 3. Remuneration to the Company's auditor The general meeting unanimously approved the remuneration to the Company's auditor for the accounting year of 2021 in accordance with the information presented in the annual accounts for the Company for 2021. 4. Election of members to the board of directors The general meeting unanimously resolved the nomination committee’s proposal of the Company’s Board of Directors. The Company's Board of Directors is as follows: - Per Matsson – Chairperson - Andrew Stapleton – Board member - Rune Sørum – Board member - Camilla Huse Bondesson – Board Member - Staffan Strömberg – Board member 5. Remuneration of the board of directors The general meeting unanimously resolved the following board remuneration to apply in the period until the next ordinary general meeting: Per Matsson – Chairperson; Remuneration of NOK 400.000 per year and 225.000 share options earned over a 3-year period at a strike price of NOK 4.00. Camilla Huse Bondesson – Board member; Remuneration of NOK 125.000 per year and 36.666 share options earned over a 3-year period at a strike price of NOK 4.00. These share options are in addition to the 33.334 options granted in 2020. Staffan Strömberg – Board member; Remuneration of NOK 125.000 per year and 36.666 share options earned over a 3-year period at a strike price of NOK 4.00. These share options are in addition to the 33.334 options granted in 2020. Rune Sørum – Board member; Remuneration of NOK 125.000 per year and 70.000 share options earned over a 3-year period at a strike price of NOK 4.00. 6. Election of the nomination committee In accordance with the proposal of the board of directors the general meeting reelected Kari Stenersen as Chair of the nomination committee. Thorvald Steen and Eilert Aamodt were elected as members. The decision was not unanimously adopted. cf. Appendix 2 to these minutes. 7. Remuneration to the Company's nomination committee In accordance with the proposal of the board of directors The general meeting resolved the following board remuneration to apply in the period until the next ordinary general meeting: Kari Stenersen – Chairperson; Remuneration NOK 15.000 per year. The decision was not unanimously adopted. cf. Appendix 2 to these minutes. 8. Extension of share option program The general meeting unanimously resolved the following resolution: 1 900 000 shares in the Company. The allocation of options shall be made by the board of directors, and each option shall entitle the holder to subscribe for a share in the Company to the value the board of directors considers as the estimated market value at the time of issue of the option. 9. Authorisation to the board of directors to increase the share capital In accordance with the proposal of the board of directors the general meeting resolved as follows: The decision was not unanimously adopted. cf. Appendix 2 to these minutes. For further information, please contact: About Genetic Analysis:
Ronny Hermansen, Chief Executive Officer
E-mail: rh@genetic-analysis.com
Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 10 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs 24 highly qualified employees with relevant scientific backgrounds and with competence in bioinformatics, molecular biology, and bioengineering. www.genetic-analysis.com